Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2021
AstraZeneca vaccine fears may be more deadly than any side effect
16 March 2021 - In Europe, vaccination against COVID-19 is off to a worryingly slow start. Just 11 doses for every ...
Posted by Michael Wonder on 16 Mar 2021
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer
16 March 2021 - New approval provides Canadian patients with HER2 positive early breast cancer a proven treatment regimen in a ...
Posted by Michael Wonder on 16 Mar 2021
ATAGI statement in response to European decisions about the AstraZeneca vaccine
16 March 2021 - ATAGI notes the suspension of the AstraZeneca vaccine program in several European countries due to reports ...
Posted by Michael Wonder on 16 Mar 2021
EU regulators team up with U.S. and UK on pharmaceutical mergers
16 March 2021 - EU antitrust enforcers have teamed up with their U.S. and British counterparts to share expertise on ...
Posted by Michael Wonder on 16 Mar 2021
Merck receives priority review from FDA for new drug application for HIF-2α inhibitor belzutifan (MK-6482)
16 March 2021 - Application based on objective response rate from Phase 2 trial evaluating belzutifan in patients with von Hippel-Lindau ...
Posted by Michael Wonder on 16 Mar 2021
Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues
16 March 2021 - EMA’s safety committee (PRAC) made further progress today in its detailed evaluation of cases of blood clots, ...
Posted by Michael Wonder on 16 Mar 2021
Doctors complain of ‘gag’ over AstraZeneca vaccine
16 March 2021 - High-profile doctors have complained they are being gagged from speaking out about their concerns on the ...
Posted by Michael Wonder on 15 Mar 2021
Facebook to label all posts about coronavirus vaccines
15 March 2021 - Facebook, which has been criticised by politicians and researchers for allowing vaccine misinformation to spread on ...
Posted by Michael Wonder on 15 Mar 2021
Confirmation of Technigas US FDA timetable
12 March 2021 - Cyclopharm has provided an update of the US FDA’s timetable in respect of approval of the Company’s ...
Posted by Michael Wonder on 15 Mar 2021
Multiple countries pause AstraZeneca vaccine use
16 March 2021 - Germany, France and Italy are the latest countries to have suspended the AstraZeneca vaccine over blood clotting ...
Posted by Michael Wonder on 15 Mar 2021
Melinta Therapeutics announces FDA approval of Kimyrsa (ortivancin) for the treatment of adult patients with acute bacterial skin and skin structure infections
15 March 2021 - Single dose antibiotic with one hour infusion, additional compatibilities in normal saline and D5W, and lower infusion ...
Posted by Michael Wonder on 15 Mar 2021
PharmaEssentia provides U.S. regulatory update on ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
14 March 2021 - PharmaEssentia Corporation today announced that the U.S. FDA has issued a complete response letter for the ...
Posted by Michael Wonder on 15 Mar 2021
EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
15 March 2021 - Several authorities responsible for national vaccine campaigns in EU countries have temporarily paused vaccination with COVID-19 Vaccine ...
Posted by Michael Wonder on 15 Mar 2021
BioXcel Therapeutics receives FDA breakthrough therapy designation for BXCL501 for the acute treatment of agitation associated with dementia
15 March 2021 - Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options ...
Posted by Michael Wonder on 15 Mar 2021
Calliditas announces submission of new drug application to U.S. FDA for Nefecon in patients with primary IgA nephropathy
15 March 2021 - Calliditas Therapeutics today announced the submission of a new drug application to the U.S. FDA for ...